Needham & Company Reiterates a 'Buy' on Optimer Pharmaceuticals (OPTR); Dificid Hits Sales Goal under Cubist Collaboration

Needham & Company reiterates a 'Buy' on Optimer Pharmaceuticals (NASDAQ: OPTR) price target of $19.00.

Analyst, Alan Carr, said, "Optimer reported $14.4M in 1Q12 Dificid net sales. Gross sales of $16.45M were preannounced in April. GAAP Diluted EPS of $(0.23) was above our $(0.63) estimate because of a $23.8M gain from OBI reconsolidation. The company also announced that it now expects to exceed the first year sales target under the Cubist (Nasdaq: CBST) commercialization deal, triggering recognition of incentive payments to Cubist. Management, however, did not provide Dificid sales or OpEx guidance. We continue to believe Dificid commercial potential is underappreciated." (Raising FY12 EPS loss from (1.92) to (0.99))

For an analyst ratings summary and ratings history on Optimer Pharmaceuticals click here. For more ratings news on Optimer Pharmaceuticals click here.

Shares of Optimer Pharmaceuticals closed at $14.80 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat